アイルランド - 英語 - HPRA (Health Products Regulatory Authority)

seqirus s.r.l. - a/michigan/45/2015 (h1n1) pdm09 - like strain (a/singapore/gp1908/2015, ivr-180a); a/singapore/imfimh-16-0019/2016 (h3n2)-like strain (a/singapore/infimh-16-0019/2016,nib-104); b/colorado/06/2017-like strain (b/victoria/2/87 lineage)(b/maryland/15/2016,nymc bx-69a) - suspension for injection in pre-filled syringe - 0.5 millilitre(s) - influenza vaccines; influenza, inactivated, split virus or surface antigen - influenza vaccine - active immunisation against influenza in the elderly (65 years of age and over. refer to spc for detailed information.

フィリピン - 英語 - FDA (Food And Drug Administration)

sanofi pasteur, inc.; distributor: zuellig pharma corporation - quadrivalent seasonal influenza vaccine (split) virion, inactivated) 2024 southern hemisphere strain. - suspension for injection (im) - formulation: each dose (0.5 ml) contains the following influenza strains*: a/sydney/5/2021 (h1n1) pdm09-like virus (a/sydney/5/2021, san-013) 15 μg of ha** a/darwin/9/2021 (h3n2)-like virus (a/darwin/9/2021, ivr-228) 15 μg of ha** b/austria/1359417/2021 (b/victoria lineage)-like virus (b/michigan/01/2021, wild type) 15 μg of ha** b/phuket/3073/2013 (b/yamagata lineage)-like virus (b/phuket/3073/2013, wild type) 15 μg of ha** *propagated in fertilized hen's eggs from healthy chicken flocks **haemagglutinin

フィリピン - 英語 - FDA (Food And Drug Administration)

glaxosmithkline philippines, inc.; distributor: glaxosmithkline philippines, inc. - quadrivalent seasonal influenza vaccine (split virion, inactivated) southern hemisphere 2024 strain. - suspension for injection (im) - formulation: each dose (0.5 ml) contains:* a/sydney/5/2021 (h1n1)pdm09-like strain 15 μg ha** (a/sydney/5/2021, ivr-229) a/darwin/9/2021 (h3n2)-like strain 15 μg ha** (a/darwin/6/2021, ivr-227) b/austria/1359417/2021-like strain 15 μg ha** (b/austria/1359417/2021, bvr-26) [victoria lineage] b/phuket/3073/2013-like strain 15 μg ha** (b/phuket/3073/2013, wild type) [yamagata lineage] *propagated in embryonated eggs **haemagglutinin

欧州連合 - 英語 - EMA (European Medicines Agency)

astrazeneca ab - reassortant influenza virus (live attenuated) of the following strain: a/vietnam/1203/2004 (h5n1) strain - influenza, human - vaccines - prophylaxis of influenza in an officially declared pandemic situation in children and adolescents from 12 months to less than 18 years of age.pandemic influenza vaccine h5n1 astrazeneca should be used in accordance with official guidance

アメリカ合衆国 - 英語 - NLM (National Library of Medicine)

novartis vaccines and diagnostics limited - influenza a virus a/california/7/2009 x-181 (h1n1) antigen (formaldehyde inactivated) (unii: 872508x6jg) (influenza a virus a/california/7/2009 x-181 (h1n1) hemagglutinin antigen (formaldehyde inactivated) - unii:5cl7878s2q) - influenza a virus a/california/7/2009 x-181 (h1n1) antigen (formaldehyde inactivated) 15 ug in 0.5 ml

アメリカ合衆国 - 英語 - NLM (National Library of Medicine)

medimmune, llc - influenza a virus a/norway/31694/2022 (h1n1) live (attenuated) antigen (unii: fv9fgc9yzw) (influenza a virus a/norway/31694/2022 (h1n1) live (attenuated) antigen - unii:fv9fgc9yzw), influenza a virus a/norway/16606/2021 (h3n2) live (attenuated) antigen (unii: l7z42hp5rz) (influenza a virus a/norway/16606/2021 (h3n2) live (attenuated) antigen - unii:l7z42hp5rz), influenza b virus b/austria/1359417/2021 live (attenuated) antigen (unii: jv6nd6vmy5) (influenza b virus b/austria/1359417/2021 live (attenuated) - influenza a virus a/slovenia/2903/2015 (h1n1) live (attenuated) antigen 10000000 [ffu] in 0.2 ml - flumist®  quadrivalent is a vaccine indicated for active immunization for the prevention of influenza disease caused by influenza a subtype viruses and type b viruses contained in the vaccine [see description (11)] . flumist quadrivalent is approved for use in persons 2 through 49 years of age. do not administer flumist quadrivalent to persons who have had a severe allergic reaction (e.g., anaphylaxis) to any component of the vaccine [see description (11)] including egg protein, or after a previous dose of any influenza vaccine. do not administer flumist quadrivalent to children and adolescents through 17 years of age who are receiving aspirin therapy or aspirin-containing therapy because of the association of reye’s syndrome with aspirin and wild-type influenza infection [see drug interactions (7.1)] . risk summary flumist quadrivalent is not absorbed systemically following intranasal administration and maternal use is not expected to result in fetal exposure to the drug. clinical considerations disease-ass

オーストラリア - 英語 - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - influenza virus haemagglutinin -

カナダ - 英語 - Health Canada

id biomedical corporation of quebec - haemagglutinin from a/california/7/2009 (h1n1)v-like strain (x-179a) - suspension - 15mcg - haemagglutinin from a/california/7/2009 (h1n1)v-like strain (x-179a) 15mcg - vaccines

ニュージーランド - 英語 - Medsafe (Medicines Safety Authority)

sanofi-aventis new zealand limited - influenza virus a/wellington/i/2004(h3n2)-like strain 10ug ([influenza virus a/wellington/i/2004 ivr-139(10 µg/ha)]);  ; influenza virus b/shanghai/361/2002-like strain 15ug ([b/jiangsu/10/2003 (15µg/ha)]);  ; influenza virus haemagglutinin type a/new caledonia/20/99 h1n1-like strain 15ug ([a/new caledonia/20/99 ivr-116 (15µg/ha)]);   - solution for injection - 10µg/15µg/15µg per dose - active: influenza virus a/wellington/i/2004(h3n2)-like strain 10ug ([influenza virus a/wellington/i/2004 ivr-139(10 µg/ha)])   influenza virus b/shanghai/361/2002-like strain 15ug ([b/jiangsu/10/2003 (15µg/ha)])   influenza virus haemagglutinin type a/new caledonia/20/99 h1n1-like strain 15ug ([a/new caledonia/20/99 ivr-116 (15µg/ha)])   excipient: dibasic sodium phosphate dihydrate monobasic potassium phosphate neomycin sodium chloride water for injection

欧州連合 - 英語 - EMA (European Medicines Agency)

novartis vaccines and diagnostics s.r.l. - influenza virus surface antigens (haemagglutinin and neuraminidase) of strain: a/california/7/2009 (h1n1)-derived strain used nymc x-181 - influenza, human; immunization; disease outbreaks - influenza vaccines - prophylaxis of influenza caused by a (h1n1v) 2009 virus.focetria should be used in accordance with official guidance.